Stock Data
$2.82 (2.61%)
Asset Type
Common Stock
Exchange
NASDAQ
Currency
USD
Country
USA
Sector
HEALTHCARE
Industry
BIOTECHNOLOGY
Corcept Therapeutics Inc is a biopharmaceutical company based in Menlo Park, California, focusing on the development of drugs to treat severe disorders such as endocrinologic, oncologic, metabolic, and neurologic conditions. Its flagship product, Korlym, helps manage hyperglycemia caused by Cushing's syndrome. The company is also advancing a robust pipeline, including relacorilant for Cushing's syndrome and other candidates targeting adrenal cancer, prostate cancer, ovarian tumors, amyotrophic lateral sclerosis, nonalcoholic steatohepatitis, and antipsychotic-induced weight gain, with several treatments in late-stage clinical trials.
Corcept crushed earnings by 671% as its newly approved cancer drug Lifyorli generated $47.6 million in its first full quarter, with over 1,300 patients already on treatment and monthly demand accelerating. The company raised full-year guidance to $1.1 billion to $1.2 billion on the strength of both the oncology launch and record new prescriptions in its core Cushing's syndrome franchise.
2 Articles
Our top personal finance-related articles today. Your wallet will thank you later.
